TIXiMED: Difference between revisions
Jump to navigation
Jump to search
(Created page with "'''TIXiMED''' is a pharmaceutical company founded in 2021 by Anath Shalev as a spinoff of her research as head of the UAB Comprehensive Diabetes Center. Michael ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:TIXiMED logo.png|right|200px]] | |||
'''TIXiMED''' is a pharmaceutical company founded in [[2021]] by [[Anath Shalev]] as a spinoff of her research as head of the [[UAB Comprehensive Diabetes Center]]. [[Michael Goodrich]] of [[First Avenue Ventures]] is co-founder and partner in the start-up, which as offices in the [[Woodward Building]]. | '''TIXiMED''' is a pharmaceutical company founded in [[2021]] by [[Anath Shalev]] as a spinoff of her research as head of the [[UAB Comprehensive Diabetes Center]]. [[Michael Goodrich]] of [[First Avenue Ventures]] is co-founder and partner in the start-up, which as offices in the [[Woodward Building]]. | ||
Latest revision as of 09:04, 27 January 2023
TIXiMED is a pharmaceutical company founded in 2021 by Anath Shalev as a spinoff of her research as head of the UAB Comprehensive Diabetes Center. Michael Goodrich of First Avenue Ventures is co-founder and partner in the start-up, which as offices in the Woodward Building.
The company's first product, the oral therapeutic "TIX100", has shown promise in inhibiting thioredoxin-interacting protein (TXNIP) production, and thereby slowing cell death related to Type I and Type II diabetes as well as to nonalcoholic fatty liver disease (NAFLD) which is often associated with diabetes. TIX100 is expected to begin in-human clinical trials in 2023.
References
- Thrailkill, Laurel (January 24, 2023) "UAB startup aiming to reverse effects of diabetes." Birmingham Business Journal
External links
- TIXiMED website